Montreal, Canada—After years of disappointing attempts to develop a vaginal microbicide that helps protect women from HIV infection, researchers announced preliminary findings from the first trial to show promising results.
New findings indicate that an experimental microbicide helps reduce risk of HIV infection.
In addition to these findings, presented at the 16th Conference on Retroviruses and Opportunistic Infections, other encouraging news on the prevention front came from studies in macaque monkeys that found that antiretroviral drugs, given by mouth or in a vaginal gel, offered some protection to the animals from infection with SHIV, a virus containing components of HIV and a related monkey virus that mimics HIV infection and causes serious illness in macaques.
Graphic Jump Location
Some tools below are only available to our subscribers or users with an online account.
Download citation file:
Web of Science® Times Cited: 2
Customize your page view by dragging & repositioning the boxes below.
More Listings atJAMACareerCenter.com >
Users' Guides to the Medical Literature
For example, a trial of intravenous immunoglobulin in advanced human immunodeficiency infection...
The Rational Clinical Examination
Evidence Summary and Review 3
All results at
Enter your username and email address. We'll send you a link to reset your password.
Enter your username and email address. We'll send instructions on how to reset your password to the email address we have on record.
Athens and Shibboleth are access management services that provide single sign-on to protected resources. They replace the multiple user names and passwords necessary to access subscription-based content with a single user name and password that can be entered once per session. It operates independently of a user's location or IP address. If your institution uses Athens or Shibboleth authentication, please contact your site administrator to receive your user name and password.